Further providing for schedules of controlled substances.
Summary
SB 899 amends Pennsylvania’s Controlled Substance, Drug, Device and Cosmetic Act to add specific restrictions on kratom products and related compounds. The bill makes it a prohibited act to prepare, manufacture, sell, or distribute a kratom product to a minor if the product is adulterated, contains certain poisonous or controlled-substance ingredients, has excessive residual solvents, contains more than 2% 7-hydroxymitragynine in the alkaloid fraction, includes synthetic kratom alkaloids or related compounds, or lacks adequate labeling directions and a recommended serving size.
The bill also adds a new Schedule I controlled-substance classification for material containing 7-hydroxymitragynine at or above 2% of total alkaloid content or 1 milligram per recommended serving size, as well as synthetic, semi-synthetic, or chemically manipulated forms of mitragynine, 7-hydroxymitragynine, mitragynine pseudoindoxyl, and related derivatives or analogues of the kratom plant. It creates criminal penalties for violations, with processors subject to a first-degree misdemeanor and non-processors subject to a second-degree misdemeanor. The act takes effect 60 days after enactment.
Impact
SB 899 would expand Pennsylvania’s controlled-substance law by expressly regulating kratom products and by placing certain high-concentration or chemically altered kratom-related compounds into Schedule I. It would affect manufacturers, processors, retailers, and distributors of kratom products, while also creating a limited good-faith reliance defense for retailers who rely on processors’ representations. The bill would also give state enforcement authorities clearer statutory grounds to pursue criminal penalties for adulterated or improperly labeled kratom products and for synthetic or concentrated kratom derivatives.
Sentiment
The available voting history suggests the bill had solid but not unanimous support in the Senate Health & Human Services Committee, with both the amendment and the amended bill reported by 9-3 votes. That pattern indicates general committee approval of tighter kratom regulation, while also showing that a meaningful minority had reservations. No committee transcript is available, so the record does not show detailed floor debate or specific arguments beyond the committee vote split.
Contention
The main points of contention likely center on whether kratom should be treated as a controlled substance and how broadly the state should regulate products derived from it. Supporters appear to favor consumer protection, especially for minors, and restrictions on adulterated, synthetic, or highly concentrated products. Opponents or skeptics may be concerned about criminalizing a product used by some adults, the breadth of the Schedule I language, and the practical burden on retailers who may have limited ability to verify product composition beyond processor assurances.
Controlled substances: other; sentencing guidelines for retail sale of products containing ephedrine or pseudoephedrine; modify. Amends sec. 13m, ch. XVII of 1927 PA 175 (MCL 777.13m). TIE BAR WITH: HB 4947'25